-
Mashup Score: 23
Physical function is a predictive and prognostic marker that complements ECOG-PS, supporting its use in informing therapy decisions for daratumumab-based treatments.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
Myeloma Paper of the Day, March 10th, suggested by Robert Orlowski / BCMA-negative myeloma, cancer, CAR-T therapy, Guixiang Wang, Jiahuan Chen, Jianqing Mi,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: Myeloma Paper of the Day, March 10th, suggested by Robert Orlowski (@Myeloma_Doc) https://t.co/CHOJ44OupS #OncoDaily #…
-
-
Mashup Score: 0Myeloma cell intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy - PubMed - 7 day(s) ago
Multiple myeloma (MM) relapse still occurs after a durable response to anti-BCMA chimeric antigen receptor-engineered T (CAR-T) cell therapy with less-defined factors. Herein, we investigated a CAR-T-exposed MM patient who relapsed after 12 months of remission by single-cell transcriptome sequencing …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
#Myeloma Paper of the Day: Myeloma cell intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy, and ANXA1 inhibition may effectively diminish BCMA-negative myeloma: https://t.co/CClCmZCuik. #mmsm https://t.co/WjvAFXOXRC
-
-
Mashup Score: 1
Myeloma Paper of the Day, March 9th, suggested by Robert Orlowski / cancer, Caroline Fidalgo Ribeiro, Eugenio Morelli, Massimo Loda, multiple myeloma, Myeloma
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: Myeloma Paper of the Day, March 9th, suggested by Robert Orlowski @Myeloma_Doc https://t.co/qRwF997UzD #Cancer #CancerRe…
-
-
Mashup Score: 0-----Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma - PubMed - 8 day(s) ago
ACC1 is a metabolic vulnerability in MYC-driven MM. Inhibiting ACC1 disrupts lipid homeostasis, induces ER stress, and causes oxidative damage, impairing cell survival. Targeting lipid synthesis pathways, especially in MYC-dependent subtypes, offers a promising therapeutic strategy for MM.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
#Myeloma Paper of the Day: ACC1 (Acetyl-CoA carboxylase) is a metabolic vulnerability in MYC-driven myeloma & inhibiting ACC1 disrupts lipid homeostasis, induces ER stress, and causes oxidative damage, impairing cell survival: https://t.co/mCEP9fC6hy. #mmsm https://t.co/DdDomuXnm1
-
-
Mashup Score: 1Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma - PubMed - 10 day(s) ago
Aberrant alternative splicing is one of the hallmarks of cancer and is potentially based on upregulated expression of splicing factors in some types of cancer. Our previous study suggested that the splicing factor RBM39 is significantly upregulated in multiple myeloma (MM) and that its upregulation …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
#Myeloma Paper of the Day: Survival and proliferation of myeloma cells rely on splicing factor RBM39, and targeting RBM39 or MEK5 synergistically increases the cytotoxicity of bortezomib in myeloma cells via the inhibition of p65: https://t.co/O9VsRbqxIF. #mmsm https://t.co/ie3Qro0EOh
-
-
Mashup Score: 3Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody - PubMed - 22 day(s) ago
Chimeric antigen receptor (CAR) T cells and bispecific T cell engagers have become integral components in the treatment of relapsed/refractory multiple myeloma. We report a 63-year-old male who received ciltacabtagene autoleucel CAR T cells and the GPRC5D × CD3 bispecific talquetamab for early relap …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
#Myeloma Paper of the Day: Multiomic profiling of T cell lymphoma after tx w/ anti-BCMA CAR T cells & GPRC5D-directed bispecific antibody in a myeloma patient w/ 3 distinct integration sites within ZGPAT, KPNA4 & polycomb-associated noncoding RNAs: https://t.co/XRQx5e12Xt. #mmsm https://t.co/2yhWyVDfbi
-
-
Mashup Score: 7High WEE1 expression is independently linked to poor survival in multiple myeloma - PubMed - 23 day(s) ago
Current prognostic scores in multiple myeloma (MM) currently rely on disease burden and a limited set of genomic alterations. Some studies have suggested gene expression panels may predict clinical outcomes, but none are presently utilized in clinical practice. The tyrosine kinase WEE1 is a critical …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
#Myeloma Paper of the Day: WEE1 expression is prognostic independent of known biomarkers, differentiates outcomes associated w/ known markers, is upregulated independently of its interacting neighbors, & is associated w/ dysregulated P53 pathways: https://t.co/7crCzAKbiI. #mmsm https://t.co/205gRaESwv
-
-
Mashup Score: 1
Myeloma Paper of the Day, February 17th, suggested by Robert Orlowski / Albert Oriol, cancer, David Moreno, Javier de la Rubia, Joan Bladé, Laura Rosiñol,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: Myeloma Paper of the Day, February 17th, suggested by @Myeloma_Doc https://t.co/GcMcB3XSAu #OncoDaily #Oncology #Cancer…
-
-
Mashup Score: 9Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials - PubMed - 28 day(s) ago
TE NDMM patients harboring t(11;14) had an inferior outcome compared with SR patients when receiving induction therapy with VTD while no differences were observed when receiving a lenalidomide containing regimen.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
#Myeloma Paper of the Day: Transplant eligible newly diagnosed myeloma patients w/ t(11;14) have inferior outcomes compared with standard risk patients when receiving induction therapy with VTD, though not if they get VRD induction therapy: https://t.co/NqjqDV8yKm. #mmsm https://t.co/9CbP1JVr3h
-
#Myeloma Paper of the Day: Study of patient-reported outcomes and survival & adverse events in daratumumab-treated myeloma finds (surprisingly!) low physical function patients experienced greater OS and PFS benefit: https://t.co/tcctIL2L6p. #mmsm https://t.co/jYjz976SKS